Non-diabetic Glucose levels and Cancer Mortality: A Literature Review

Abstract

In these studies reviewed, cancer mortality increased in individuals with an increased glucose concentration and an increased potential was seen in those patients with glucose intolerance even at non-diabetic glucose levels. The outcome of these findings is promising and forms the basis for further studies to directly address the relevance of increased (non-diabetic) glucose and glucose intolerance as a prognostic indicator of cancer mortality.

Targeting the Supply Lines of Cancer – A Possible Strategy for Combating the Disease?

“…The study found that higher blood glucose concentrations could be seen to significantly associate with higher rates of cancer-related deaths, whereas no such association was found among participants presenting normoglycemic levels (13). Furthermore, these associations can also be observed at elevated blood glucose concentrations that are still below the diabetic range (12)(13)(14). Similar findings are also reported in other relatively large studies (15)(16)(17).…”

A potent physiological method to magnify and sustain soleus oxidative metabolism improves glucose and lipid regulation

“…Statistically significant differences lasted until at least 180 min. The separation in glucose concentration between the sedentary control and activity trials expanded up until ∼75–135 min ( Table 3 ); this coincides with about the time frame most commonly studied when relating glucose to clinically meaningful pathologies ( Buysschaert et al., 2015 ; DeFronzo and Abdul-Ghani, 2011 ; Festa et al., 2004 ; Kakehi et al., 2018 ; Ohara et al., 2011 ; Papanas et al., 2011 ; Succurro et al., 2009 ).…”

“…There is also currently a high prevalence of prolonged sitting between 9 and 11 h/day ( Craft et al., 2012 ; Healy et al., 2015 ; Matthews et al., 2018 ; van der Berg et al., 2016 ) at a low metabolic rate during seated behaviors ( Newton et al., 2013 ), especially in people who are at high risk for age-associated metabolic diseases such as metabolic syndrome and type 2 diabetes ( van der Berg et al., 2016 ). Even in nondiabetics, postprandial glucose concentration in the 60–120 min range of an oral glucose tolerance test (OGTT) has often been described as one of the strongest independent metabolic risk factors for chronic disease because of linkages to Alzheimer disease ( Kakehi et al., 2018 ; Ohara et al., 2011 ), neuropathies ( Buysschaert et al., 2015 ; Papanas et al., 2011 ), dyslipidemia ( DeFronzo and Abdul-Ghani, 2011 ; Festa et al., 2004 ), and cardiovascular conditions ( DeFronzo and Abdul-Ghani, 2011 ; Succurro et al., 2009 ). Of concern, glucose tolerance is relatively difficult to improve by a meaningful amount during most therapies, including after substantial amounts of weight loss or exercise ( Jansen et al., 2022 ; King et al., 1995 ; Knudsen et al., 2014 ; Magkos et al., 2016 ; Rose et al., 2001 ; Ross et al., 2000 , 2015 ; Slentz et al., 2016 ).…”

Alterations in the gastric microbiota and metabolites in gastric cancer: An update review

“…Studies have reported that in non-diabetic conditions, blood glucose levels are positively correlated with cancer mortality, and the potential mortality of cancer patients with glucose intolerance is also increased ( 76 ). Hyperglycemia in patients with both diabetes and GC can promote the proliferation of GC cells and reduce the sensitivity to chemotherapeutic drugs ( 77 ). Not only that, glycolysis transcriptional regulators and glycolysis-related proteins are significantly correlated with the prognosis of cancer patients, so glycolysis status may also be a potential biomarker for prognosis ( 78 ).…”